Skip to main content
. 2022 Jan 27;12:820191. doi: 10.3389/fphar.2021.820191

FIGURE 3.

FIGURE 3

Combination of venetoclax and sunitinib. (A) Cell viability of SHI-1 and NOMO-1 [both KMT2A-rearranged acute myeloid leukemia (AML)] and HL-60 (non-KMT2A-rearranged AML) after treatment with sunitinib combined with venetoclax at 48 h after treatment. The synergy scores were represented by pseudocoloring 2-dimensional contour plots over the dose matrix (red indicates synergy and green indicates antagonism) and calculated using the ZIP model (synergy when >10, n = 2). Stars indicate the concentrations selected for subsequent experiments. (B) Cell viability of SHI-1 and NOMO-1 (KMT2A-arranged) or HL-60 (non-KMT2A-rearranged) after treatment with venetoclax, sunitinib, or the combination at 48 h after treatment (CI, combination index; synergy when CI <1. ANOVA test was performed by applying Bonferroni correction for multiple statistical hypotheses testing. *p < 0.05; **p < 0.01, ***p < 0.001; ****p < 0.0001; n = 2). (C) MCL-1 and BCL-2 levels measured at 48 h post-treatment in SHI-1 and NOMO-1. Histograms report the quantification normalized to GAPDH. ANOVA test was performed by applying Bonferroni correction for multiple statistical hypotheses testing. *p < 0.05, **p < 0.01, ***p < 0.001; n = 2.